Newborn affected by maternal use of amphetamines
ICD-10 P04.16 is a billable code used to indicate a diagnosis of newborn affected by maternal use of amphetamines.
Newborns affected by maternal use of amphetamines may present with a range of symptoms due to the exposure to these noxious substances during pregnancy. Amphetamines can cross the placenta and affect fetal development, leading to potential complications such as low birth weight, preterm birth, and withdrawal symptoms post-delivery. Clinical manifestations in the newborn may include irritability, feeding difficulties, tremors, and increased muscle tone. These infants may also exhibit signs of neonatal abstinence syndrome (NAS), which can complicate their care in the neonatal intensive care unit (NICU). The management of these newborns often requires a multidisciplinary approach, including pediatricians, neonatologists, and social services, to address both the medical and psychosocial needs of the infant and family. Accurate coding is essential for appropriate treatment planning and resource allocation, as well as for tracking outcomes related to maternal substance use during pregnancy.
Detailed maternal history, including substance use patterns, and newborn assessment findings.
Infants presenting with irritability, feeding intolerance, and tremors in the NICU.
Consideration of potential long-term developmental assessments and follow-up care.
Documentation of developmental milestones and any ongoing treatment for withdrawal symptoms.
Pediatric follow-up visits for infants with a history of maternal amphetamine use.
Monitoring for behavioral and developmental issues as the child grows.
Used for newborns affected by maternal amphetamine use requiring initial assessment.
Document maternal history and newborn assessment findings.
Neonatologists should ensure comprehensive evaluations are conducted.
Common symptoms include irritability, feeding difficulties, tremors, and signs of withdrawal. These infants may require specialized care in the NICU.
